New malaria combo shows promise in kids
NCT ID NCT04546633
First seen May 15, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tested a new combination of two drugs, KAF156 and lumefantrine, in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment works well and is safe, and to offer a new option that may help prevent drug resistance. The study found that the combination was effective in clearing the malaria parasite by day 29.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Banfora, Burkina Faso
-
Novartis Investigative Site
Bobo-Dioulasso, 01, Burkina Faso
-
Novartis Investigative Site
Ouagadougou, Burkina Faso
-
Novartis Investigative Site
Sabou, 06 BP 10248, Burkina Faso
-
Novartis Investigative Site
Abidjan, 13BP972, Côte d’Ivoire
-
Novartis Investigative Site
Lambaréné, BP 242, Gabon
-
Novartis Investigative Site
Kati, Mali
-
Novartis Investigative Site
Sotouba, Mali
-
Novartis Investigative Site
Lubumbashi, Du Haut Katanga, 7010, Republic of the Congo
Conditions
Explore the condition pages connected to this study.